secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001140361-23-009574
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin completes NAVIGATE randomization with 357 patients; topline results Q4 2024
--------------------------------------------------------------------------------

- Randomized 357 patients, exceeding initial target of ~315, in Phase 2b/3 belapectin study for NASH cirrhosis.
- Last patient randomized end of February 2023; enrollment of new patients ended in late December 2022.
- Study is first to evaluate primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.
- Topline interim results from Phase 2b portion expected in Q4 2024.
- Trial enrolled patients across 14 countries on five continents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123009574/0001140361-23-009574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123009574/brhc10049140_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-009574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer